S-8

As filed with the Securities and Exchange Commission on March 15, 2021

Registration No. 333-            

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

LOGICBIO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   47-1514975

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

66 Hayden Avenue, 2nd Floor

Lexington, MA

  02421
(Address of Principal Executive Offices)   (Zip Code)

2018 Equity Incentive Plan

2018 Employee Stock Purchase Plan

(Full titles of the plans)

Frederic Chereau

President and Chief Executive Officer

LogicBio Therapeutics, Inc.

66 Hayden Avenue, 2nd Floor

Lexington, MA 02421

(Name and address of agent for service)

(617) 245-0399

(Telephone number, including area code, of agent for service)

Please send copies of all communications to:

Marc A. Rubenstein

Ropes & Gray LLP

Prudential Tower

800 Boylston Street

Boston, MA 02199-3600

617-951-7000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☒

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Securities

to be Registered

 

Amount

to be
Registered (1)

  Proposed
Maximum
Offering Price
Per Share
 

Proposed
Maximum
Aggregate

Offering Price

 

Amount of

Registration Fee

LogicBio Therapeutics, Inc. 2018 Equity Incentive Plan – Common Stock, $0.0001 par value per share

  1,272,547 shares(2)   $7.87(3)   $10,014,944.89   $ 1,092.63

LogicBio Therapeutics, Inc. 2018 Employee Stock Purchase Plan – Common Stock, $0.0001 par value per share

  318,136 shares(4)   $7.87(5)   $ 2,503,730.32   $ 273.16

TOTAL

  1,590,683 shares       $12,518,675.21   $ 1,365.79

 

 

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, this Registration Statement also covers such additional shares of Common Stock as may issued to prevent dilution from stock splits, stock dividends and similar transactions.

(2)

Represents shares of Common Stock automatically added to the shares authorized under the LogicBio Therapeutics, Inc. 2018 Equity Incentive Plan (the “2018 Incentive Plan”) on January 1, 2021 pursuant to an “evergreen” provision contained in the 2018 Incentive Plan. The “evergreen” provision provides that on each January 1st through January 1, 2028, the number of shares of Common Stock available for issuance under the 2018 Incentive Plan will automatically increase annually in an amount equal to the lesser of 4% of outstanding shares of the registrant’s Common Stock as of the close of business on the immediately preceding December 31st or the number of shares determined by the registrant’s board of directors.

(3)

Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) based on the average of the high and low prices of the registrant’s Common Stock as reported on the Nasdaq Global Market on March 8, 2021 to be $8.13 and $7.60, respectively.

(4)

Represents shares of Common Stock that were automatically added to the shares authorized under the LogicBio Therapeutics, Inc. 2018 Employee Stock Purchase Plan (the “2018 ESPP”) on January 1, 2021 pursuant to an “evergreen” provision contained in the 2018 ESPP. The “evergreen” provision provides that on each January 1st through January 1, 2028, the number of shares of Common Stock available for issuance under the 2018 ESPP will automatically increase annually in an amount equal to the lesser of 1% of outstanding shares of the registrant’s Common Stock as of the close of business on the immediately preceding December 31st or the number of shares determined by the registrant’s board of directors.

(5)

Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) based on the average of the high and low prices of the registrant’s Common Stock as reported on the Nasdaq Global Market on March 8, 2021 to be $8.13 and $7.60, respectively.

 

 

 


EXPLANATORY NOTE

This Registration Statement has been filed by LogicBio Therapeutics, Inc. (the “Registrant”) to register 1,272,547 additional shares of common stock to be offered pursuant to the LogicBio Therapeutics, Inc. 2018 Equity Incentive Plan and 318,136 additional shares of common stock to be offered pursuant to the LogicBio Therapeutics, Inc. 2018 Employee Stock Purchase Plan.

This Registration Statement relates to securities of the same class as those that were previously registered by the Registrant on Form S-8 (File No. 333-230689), filed with the Securities and Exchange Commission on April 2, 2019 (the “2019 Registration Statement”). Pursuant to General Instruction E to Form S-8 regarding registration of additional securities, the entire contents of the 2019 Registration Statement are incorporated herein by reference.


PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

 

Exhibit     
  4.1    Fourth Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to the current report Form 8-K filed on October 29, 2018 (File No. 001-38707) and incorporated herein by reference).
  4.2    Amended and Restated Bylaws (previously filed as Exhibit 3.2 to the current report Form 8-K filed on October 29, 2018 (File No. 38707) and incorporated herein by reference).
  4.3    LogicBio Therapeutics, Inc. 2018 Equity Incentive Plan (previously filed as Exhibit 10.11 to the registration statement on Form S-1 (File No. 333-227523) and incorporated herein by reference).
  4.4    LogicBio Therapeutics, Inc. 2018 Employee Stock Purchase Plan (previously filed as Exhibit 10.9 to the registration statement on Form S-1 (File No. 333-227523) and incorporated herein by reference).
  5.1    Opinion of Ropes & Gray LLP.
23.1    Consent of Independent Registered Public Accounting Firm.
23.2    Consent of Ropes & Gray LLP (included in the opinion filed as Exhibit 5.1).
24.1    Powers of Attorney (included on the signature page in Part II).


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lexington, Commonwealth of Massachusetts, on this 15th day of March, 2021.

 

LOGICBIO THERAPEUTICS, INC.
By:  

/s/ Frederic Chereau

  Name:   Frederic Chereau
  Title:   President and Chief Executive Officer

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Frederic Chereau, Kyle Chiang and Cecilia Jones, and each of them acting individually, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by LogicBio Therapeutics, Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

* * * *

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

 

Signature

  

Title

 

Date

/s/ Frederic Chereau

  

President, Chief Executive Officer and Director

(Principal Executive Officer)

  March 15, 2021
Frederic Chereau

/s/ Cecilia Jones

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

  March 15, 2021
Cecilia Jones

/s/ Leon Chen

   Director   March 15, 2021
Leon Chen, Ph.D.

/s/ Mark Enyedy

   Director   March 15, 2021
Mark Enyedy

/s/ Jeff Goater

   Director   March 15, 2021
Jeff Goater

/s/ Daphne Karydas

   Director   March 15, 2021
Daphne Karydas

/s/ Mark Kay

   Director   March 15, 2021
Mark Kay, M.D., Ph.D.


/s/ Richard Moscicki

   Director   March 15, 2021
Richard Moscicki, M.D.

/s/ Michael Wyzga

   Director   March 15, 2021
Michael Wyzga
EX-5.1

Exhibit 5.1

 

LOGO

  

ROPES & GRAY LLP

PRUDENTIAL TOWER

800 BOYLSTON STREET

BOSTON, MA 02199-3600

WWW.ROPESGRAY.COM

March 15, 2021

LogicBio Therapeutics, Inc.

66 Hayden Avenue, 2nd Floor

Lexington, MA 02421

Ladies and Gentlemen:

This opinion letter is furnished to you in connection with the registration statement on Form S-8 (the “Registration Statement”), filed by LogicBio Therapeutics, Inc., a Delaware corporation (the “Company”), on the date hereof, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), for the registration of 1,590,683 shares of common stock, $0.0001 par value, of the Company (the “Shares”). The Shares are issuable under the LogicBio Therapeutics, Inc. 2018 Equity Incentive Plan and the LogicBio Therapeutics, Inc. 2018 Employee Stock Purchase Plan (each, a “Plan,” and collectively, the “Plans”).

We are familiar with the actions taken by the Company in connection with the adoption of the Plans. We have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.

The opinions expressed below are limited to the Delaware General Corporation Law.

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the terms of the applicable Plan, will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Ropes & Gray LLP

Ropes & Gray LLP

EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 15, 2021, relating to the financial statements of LogicBio Therapeutics, Inc. appearing in the Annual Report on Form 10-K of LogicBio Therapeutics, Inc. for the year ended December 31, 2020.

 

/s/ Deloitte & Touche LLP

Boston, Massachusetts

March 15, 2021